The implementation of H6159 is set to take effect for health plans that are entered into, amended, extended, or renewed on or after January 1, 2024. This timeline provides insurers and health plan managers a window to adjust their policies in accordance with the new regulations. The bill addresses a vital area of healthcare coverage, potentially improving the financial predictability for enrollees by ensuring that third-party payments are factored into the overall cost-sharing calculations.
Summary
House Bill 6159 introduces significant amendments to the existing prescription drug benefits regulations in Rhode Island. The primary focus of the bill is to include all costs paid by an enrollee or on behalf of the enrollee by a third party when calculating their total contribution toward any out-of-pocket maximum or cost-sharing requirements under health plans. This change aims to ensure that individuals are not burdened with unforeseen costs when accessing prescription drug coverage.
Contention
Notably, the bill does not seem to have been met with significant opposition in discussions or voting history, indicating broad legislative support for its provisions. However, the inclusion of third-party payments in cost calculations may invite scrutiny regarding the financial implications for health plan providers. The adjustments could require updates in internal accounting practices for insurers and pharmacy benefit managers, which may be a point of discussion as the effective date approaches.
An act to amend Section 4073.5 of the Business and Professions Code, to amend Section 1367.22 of the Health and Safety Code, and to add Section 10123.190 to the Insurance Code, relating to prescription drugs.
Prohibits pre-approval or precertification of medical tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.
Prohibits pre-approval or precertification of medical tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.
Prohibits pre-approval or precertification of cancer treatments, tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.